VivoSeq
Other

Plaque

0

Pipeline Programs

1

Active Trials

3

Companies Involved

Plaque is an early-stage landscape with 0 programs across 3 companies. The most active players are Pfizer, Merck & Co., Bayer.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

9/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

33

clinical trials

Completed24 · 73%
Unknown status5 · 15%
Terminated3 · 9%
Not yet recruiting1 · 3%

Trial Activity

33 trials

Train New Examiners Via Modified Gingival Margin Plaque
Completed··Phase 3·NCT00758563·15 enrolled
Evaluating Commercial Anti-Plaque Products and Oral Rinse
Completed··Phase 2·NCT01014143·26 enrolled
Metagenomic and Metatranscriptomic Analysis of Clinical Plaque Samples
Completed··Phase 2·NCT05138978·34 enrolled
Effect of Evolocumab on Coronary Plaque Characteristics
Completed··Phase 4·NCT04710368·137 enrolled
Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy
Completed··Phase 4·NCT01567826·87 enrolled
Effect on Bacterial Glycolytic Acid Formation on Plaque
Completed··Phase 3·NCT00762450·6 enrolled
A Study to Evaluate Sampling Methods for Subgingival Plaque
Completed··N/A·NCT02841839·20 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)